Katherine E. Strathearn

4.2k total citations · 2 hit papers
12 papers, 3.4k citations indexed

About

Katherine E. Strathearn is a scholar working on Neurology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Katherine E. Strathearn has authored 12 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Neurology, 5 papers in Cellular and Molecular Neuroscience and 3 papers in Molecular Biology. Recurrent topics in Katherine E. Strathearn's work include Parkinson's Disease Mechanisms and Treatments (10 papers), Phytochemicals and Antioxidant Activities (2 papers) and Alzheimer's disease research and treatments (2 papers). Katherine E. Strathearn is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (10 papers), Phytochemicals and Antioxidant Activities (2 papers) and Alzheimer's disease research and treatments (2 papers). Katherine E. Strathearn collaborates with scholars based in United States, Australia and Portugal. Katherine E. Strathearn's co-authors include Jean‐Christophe Rochet, Kim A. Caldwell, Guy A. Caldwell, Susan Lindquist, Aaron D. Gitler, Kathryn J. Hill, Antony A. Cooper, Tiago F. Outeiro, Shusei Hamamichi and Bradley T. Hyman and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Genetics.

In The Last Decade

Katherine E. Strathearn

12 papers receiving 3.3k citations

Hit Papers

α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neur... 2006 2026 2012 2019 2006 2007 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models
    2006 1.1k citations Antony A. Cooper, Aaron D. Gitler et al. Science profile →
  2. Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease
    2007 853 citations Tiago F. Outeiro, Stephen M. Altmann et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katherine E. Strathearn United States 11 1.7k 1.3k 925 881 786 12 3.4k
Charbel Moussa United States 36 1.5k 0.9× 1.5k 1.2× 1.6k 1.7× 1.0k 1.1× 333 0.4× 83 4.2k
Esperanza Arias United States 21 596 0.4× 1.4k 1.1× 740 0.8× 589 0.7× 791 1.0× 29 3.4k
Maria Xilouri Greece 27 2.0k 1.2× 989 0.8× 1.1k 1.1× 750 0.9× 641 0.8× 48 3.5k
Jordi Bové Spain 24 2.1k 1.3× 1.5k 1.2× 946 1.0× 1.5k 1.7× 454 0.6× 35 4.3k
Eunsung Junn United States 33 2.3k 1.4× 3.0k 2.3× 1.0k 1.1× 1.6k 1.8× 409 0.5× 44 5.8k
Emma Deas United Kingdom 23 2.3k 1.4× 2.1k 1.7× 1.6k 1.8× 942 1.1× 686 0.9× 27 4.5k
Matthew E. Gegg United Kingdom 29 1.8k 1.1× 1.5k 1.2× 1.8k 2.0× 561 0.6× 1.0k 1.3× 44 4.0k
Byoung Boo Seo United States 25 925 0.6× 1.9k 1.5× 372 0.4× 677 0.8× 159 0.2× 37 3.1k
Yungui Zhou United States 22 404 0.2× 1.5k 1.2× 2.2k 2.4× 706 0.8× 293 0.4× 29 4.3k
Michaeline Hebron United States 25 886 0.5× 847 0.7× 837 0.9× 549 0.6× 188 0.2× 47 2.5k

Countries citing papers authored by Katherine E. Strathearn

Since Specialization
Citations

This map shows the geographic impact of Katherine E. Strathearn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine E. Strathearn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine E. Strathearn more than expected).

Fields of papers citing papers by Katherine E. Strathearn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine E. Strathearn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine E. Strathearn. The network helps show where Katherine E. Strathearn may publish in the future.

Co-authorship network of co-authors of Katherine E. Strathearn

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine E. Strathearn. A scholar is included among the top collaborators of Katherine E. Strathearn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine E. Strathearn. Katherine E. Strathearn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Tambe, Mitali A., Aurélie de Rus Jacquet, Katherine E. Strathearn, et al.. (2023). Protective Effects of Polyphenol-Rich Extracts against Neurotoxicity Elicited by Paraquat or Rotenone in Cellular Models of Parkinson’s Disease. Antioxidants. 12(7). 1463–1463. 10 indexed citations
2.
Landeck, Natalie, Katherine E. Strathearn, Daniel Ysselstein, et al.. (2020). Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein. Molecular Neurodegeneration. 15(1). 49–49. 12 indexed citations
3.
Ambaw, A., Lingxing Zheng, Mitali A. Tambe, et al.. (2018). Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson's disease. Molecular and Cellular Neuroscience. 88. 70–82. 39 indexed citations
4.
Strathearn, Katherine E., Gad G. Yousef, Mary H. Grace, et al.. (2014). Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson׳s disease. Brain Research. 1555. 60–77. 179 indexed citations
5.
Dumitriu, Alexandra, Jemma B. Wilk, Katherine E. Strathearn, et al.. (2011). Cyclin-G-associated kinase modifies  -synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Human Molecular Genetics. 20(8). 1478–1487. 55 indexed citations
6.
Gitler, Aaron D., Alessandra Chesi, Melissa L. Geddie, et al.. (2009). α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nature Genetics. 41(3). 308–315. 433 indexed citations
7.
Su, Linhui Julie, Pavan K. Auluck, Tiago F. Outeiro, et al.. (2009). Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models. Disease Models & Mechanisms. 3(3-4). 194–208. 143 indexed citations
8.
Outeiro, Tiago F., Stephen M. Altmann, Irina Kufareva, et al.. (2007). Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease. Science. 317(5837). 516–519. 853 indexed citations breakdown →
9.
Gitler, Aaron D., Brooke J. Bevis, James Shorter, et al.. (2007). The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis. Proceedings of the National Academy of Sciences. 105(1). 145–150. 413 indexed citations
10.
Cooper, Antony A., Aaron D. Gitler, Anil G. Cashikar, et al.. (2006). α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models. Science. 313(5785). 324–328. 1064 indexed citations breakdown →
11.
Outeiro, Tiago F., Jochen Klucken, Katherine E. Strathearn, et al.. (2006). Small heat shock proteins protect against α-synuclein-induced toxicity and aggregation. Biochemical and Biophysical Research Communications. 351(3). 631–638. 149 indexed citations
12.
Strathearn, Katherine E., et al.. (2004). Redetermination of 9-nitroanthracene at 100 K. Acta Crystallographica Section E Structure Reports Online. 60(11). o2125–o2126. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charbel Moussa Breakdown of academic impact, for papers by Esperanza Arias Breakdown of academic impact, for papers by Maria Xilouri Breakdown of academic impact, for papers by Jordi Bové Breakdown of academic impact, for papers by Eunsung Junn Breakdown of academic impact, for papers by Emma Deas Breakdown of academic impact, for papers by Matthew E. Gegg Breakdown of academic impact, for papers by Byoung Boo Seo Breakdown of academic impact, for papers by Yungui Zhou Breakdown of academic impact, for papers by Michaeline Hebron
Rankless by CCL
2026